Top

Journal of Neuro-Oncology

Published in:

01-02-2021 | Glioblastoma | Topic Review

Convection-enhanced drug delivery for glioblastoma: a review

Authors: Randy S. D’Amico, Manish K. Aghi, Michael A. Vogelbaum, Jeffrey N. Bruce

Published in: Journal of Neuro-Oncology | Issue 3/2021

Abstract

Introduction

Convection-enhanced delivery (CED) is a method of targeted, local drug delivery to the central nervous system (CNS) that bypasses the blood-brain barrier (BBB) and permits the delivery of high-dose therapeutics to large volumes of interest while limiting associated systemic toxicities. Since its inception, CED has undergone considerable preclinical and clinical study as a safe method for treating glioblastoma (GBM). However, the heterogeneity of both, the surgical procedure and the mechanisms of action of the agents studied—combined with the additional costs of performing a trial evaluating CED—has limited the field’s ability to adequately assess the durability of any potential anti-tumor responses. As a result, the long-term efficacy of the agents studied to date remains difficult to assess.

Materials and methods

We searched PubMed using the phrase “convection-enhanced delivery and glioblastoma”. The references of significant systematic reviews were also reviewed for additional sources. Articles focusing on physiological and physical mechanisms of CED were included as well as technological CED advances.

Results

We review the history and principles of CED, procedural advancements and characteristics, and outcomes from key clinical trials, as well as discuss the potential future of this promising technique for the treatment of GBM.

Conclusion

While the long-term efficacy of the agents studied to date remains difficult to assess, CED remains a promising technique for the treatment of GBM.

Bobo RH, Laske DW, Akbasak A, Morrison PF, Dedrick RL, Oldfield EH (1994) Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci USA 91:2076–2080CrossRef

D'Amico RS, Kennedy BC, Bruce JN (2014) Neurosurgical oncology: advances in operative technologies and adjuncts. J Neurooncol 119:451–463. https://doi.org/10.1007/s11060-014-1493-3CrossRefPubMed

Bruce JN, Fine RL, Canoll P, Yun J, Kennedy BC, Rosenfeld SS, Sands SA, Surapaneni K, Lai R, Yanes CL, Bagiella E, DeLaPaz RL (2011) Regression of recurrent malignant gliomas with convection-enhanced delivery of topotecan. Neurosurgery 69:1272–1279; discussion 1279-1280 https://doi.org/10.1227/NEU.0b013e3182233e24CrossRefPubMedPubMedCentral

Mehta AM, Sonabend AM, Bruce JN (2017) Convection-enhanced delivery. Neurotherapeutics 14:358–371. https://doi.org/10.1007/s13311-017-0520-4CrossRefPubMedPubMedCentral

Kunwar S (2003) Convection enhanced delivery of IL13-PE38QQR for treatment of recurrent malignant glioma: presentation of interim findings from ongoing phase 1 studies. Acta Neurochir Suppl 88:105–111PubMed

Laske DW, Youle RJ, Oldfield EH (1997) Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nat Med 3:1362–1368CrossRef

Rand RW, Kreitman RJ, Patronas N, Varricchio F, Pastan I, Puri RK (2000) Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma. Clin Cancer Res 6:2157–2165PubMed

Sampson JH, Akabani G, Archer GE, Bigner DD, Berger MS, Friedman AH, Friedman HS, Herndon JE, 2nd, Kunwar S, Marcus S, McLendon RE, Paolino A, Penne K, Provenzale J, Quinn J, Reardon DA, Rich J, Stenzel T, Tourt-Uhlig S, Wikstrand C, Wong T, Williams R, Yuan F, Zalutsky MR, Pastan I (2003) Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. J Neurooncol 65:27–35CrossRef

Weber FW, Floeth F, Asher A, Bucholz R, Berger M, Prados M, Chang S, Bruce J, Hall W, Rainov NG, Westphal M, Warnick RE, Rand RW, Rommell F, Pan H, Hingorani VN, Puri RK (2003) Local convection enhanced delivery of IL4-Pseudomonas exotoxin (NBI-3001) for treatment of patients with recurrent malignant glioma. Acta Neurochir Suppl 88:93–103PubMed

10.

Desjardins A, Gromeier M, Herndon JE, 2nd, Beaubier N, Bolognesi DP, Friedman AH, Friedman HS, McSherry F, Muscat AM, Nair S, Peters KB, Randazzo D, Sampson JH, Vlahovic G, Harrison WT, McLendon RE, Ashley D, Bigner DD (2018) Recurrent glioblastoma treated with recombinant poliovirus. N Engl J Med 379:150–161. https://doi.org/10.1056/NEJMoa1716435CrossRefPubMedPubMedCentral

11.

Jain RK (1989) Delivery of novel therapeutic agents in tumors: physiological barriers and strategies. J Natl Cancer Inst 81:570–576. https://doi.org/10.1093/jnci/81.8.570CrossRefPubMed

12.

Lonser RR, Sarntinoranont M, Morrison PF, Oldfield EH (2015) Convection-enhanced delivery to the central nervous system. J Neurosurg 122:697–706. https://doi.org/10.3171/2014.10.JNS14229CrossRefPubMed

13.

Ksendzovsky A, Walbridge S, Saunders RC, Asthagiri AR, Heiss JD, Lonser RR (2012) Convection-enhanced delivery of M13 bacteriophage to the brain. J Neurosurg 117:197–203. https://doi.org/10.3171/2012.4.JNS111528CrossRefPubMedPubMedCentral

14.

Dickinson PJ, LeCouteur RA, Higgins RJ, Bringas JR, Roberts B, Larson RF, Yamashita Y, Krauze M, Noble CO, Drummond D, Kirpotin DB, Park JW, Berger MS, Bankiewicz KS (2008) Canine model of convection-enhanced delivery of liposomes containing CPT-11 monitored with real-time magnetic resonance imaging: laboratory investigation. J Neurosurg 108:989–998. https://doi.org/10.3171/JNS/2008/108/5/0989CrossRefPubMed

15.

Huynh NT, Passirani C, Allard-Vannier E, Lemaire L, Roux J, Garcion E, Vessieres A, Benoit JP (2012) Administration-dependent efficacy of ferrociphenol lipid nanocapsules for the treatment of intracranial 9L rat gliosarcoma. Int J Pharm 423:55–62. https://doi.org/10.1016/j.ijpharm.2011.04.037CrossRefPubMed

16.

Szerlip NJ, Walbridge S, Yang L, Morrison PF, Degen JW, Jarrell ST, Kouri J, Kerr PB, Kotin R, Oldfield EH, Lonser RR (2007) Real-time imaging of convection-enhanced delivery of viruses and virus-sized particles. J Neurosurg 107:560–567. https://doi.org/10.3171/JNS-07/09/0560CrossRefPubMed

17.

Barker FG, 2nd, Chang SM, Gutin PH, Malec MK, McDermott MW, Prados MD, Wilson CB (1998) Survival and functional status after resection of recurrent glioblastoma multiforme. Neurosurgery 42:709–720; discussion 720-703CrossRef

18.

Kelly PJ, Daumas-Duport C, Kispert DB, Kall BA, Scheithauer BW, Illig JJ (1987) Imaging-based stereotaxic serial biopsies in untreated intracranial glial neoplasms. J Neurosurg 66:865–874. https://doi.org/10.3171/jns.1987.66.6.0865CrossRefPubMed

19.

Zhou Z, Singh R, Souweidane MM (2017) Convection-enhanced delivery for diffuse intrinsic pontine glioma treatment. Curr Neuropharmacol 15:116–128CrossRef

20.

Sarkaria JN, Hu LS, Parney IF, Pafundi DH, Brinkmann DH, Laack NN, Giannini C, Burns TC, Kizilbash SH, Laramy JK, Swanson KR, Kaufmann TJ, Brown PD, Agar NYR, Galanis E, Buckner JC, Elmquist WF (2018) Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data. Neuro Oncol 20:184–191. https://doi.org/10.1093/neuonc/nox175CrossRefPubMed

21.

Fokas E, Steinbach JP, Rodel C (2013) Biology of brain metastases and novel targeted therapies: time to translate the research. Biochim Biophys Acta 1835:61–75. https://doi.org/10.1016/j.bbcan.2012.10.005CrossRefPubMed

22.

Theodorakis PE, Muller EA, Craster RV, Matar OK (2017) Physical insights into the blood-brain barrier translocation mechanisms. Phys Biol 14:041001. https://doi.org/10.1088/1478-3975/aa708aCrossRefPubMed

23.

Sampson JH, Raghavan R, Brady M, Friedman AH, Bigner D (2011) Convection-enhanced delivery. J Neurosurg 115:463–464; discussion 465-466 https://doi.org/10.3171/2010.11.JNS101801CrossRefPubMed

24.

Bogdahn U, Hau P, Stockhammer G, Venkataramana NK, Mahapatra AK, Suri A, Balasubramaniam A, Nair S, Oliushine V, Parfenov V, Poverennova I (2011) Targeted therapy for high-grade glioma with the TGF-beta2 inhibitor trabedersen: results of a randomized and controlled phase IIb study. Neuro Oncol 13:132–142. https://doi.org/10.1093/neuonc/noq142CrossRefPubMed

25.

Carpentier A, Metellus P, Ursu R, Zohar S, Lafitte F, Barrie M, Meng Y, Richard M, Parizot C, Laigle-Donadey F, Gorochov G, Psimaras D, Sanson M, Tibi A, Chinot O, Carpentier AF (2010) Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study. Neuro Oncol 12:401–408. https://doi.org/10.1093/neuonc/nop047CrossRefPubMedPubMedCentral

26.

Lidar Z, Mardor Y, Jonas T, Pfeffer R, Faibel M, Nass D, Hadani M, Ram Z (2004) Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a phase I/II clinical study. J Neurosurg 100:472–479. https://doi.org/10.3171/jns.2004.100.3.0472CrossRefPubMed

27.

Patel SJ, Shapiro WR, Laske DW, Jensen RL, Asher AL, Wessels BW, Carpenter SP, Shan JS (2005) Safety and feasibility of convection-enhanced delivery of Cotara for the treatment of malignant glioma: initial experience in 51 patients. Neurosurgery 56:1243–1252; discussion 1252-1243CrossRef

28.

Voges J, Reszka R, Gossmann A, Dittmar C, Richter R, Garlip G, Kracht L, Coenen HH, Sturm V, Wienhard K, Heiss WD, Jacobs AH (2003) Imaging-guided convection-enhanced delivery and gene therapy of glioblastoma. Ann Neurol 54:479–487. https://doi.org/10.1002/ana.10688CrossRefPubMed

29.

Weaver M, Laske DW (2003) Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas. J Neurooncol 65:3–13CrossRef

30.

Souweidane MM (2014) Editorial: convection-enhanced delivery for diffuse intrinsic pontine glioma. J Neurosurg Pediatr 13:273–274. https://doi.org/10.3171/2013.10.PEDS13421CrossRefPubMed

31.

Sonabend AM, Stuart RM, Yun J, Yanagihara T, Mohajed H, Dashnaw S, Bruce SS, Brown T, Romanov A, Sebastian M, Arias-Mendoza F, Bagiella E, Canoll P, Bruce JN (2011) Prolonged intracerebral convection-enhanced delivery of topotecan with a subcutaneously implantable infusion pump. Neuro Oncol 13:886–893. https://doi.org/10.1093/neuonc/nor051CrossRefPubMedPubMedCentral

32.

Vogelbaum MA, Brewer C, Barnett GH, Mohammadi AM, Peereboom DM, Ahluwalia MS, Gao S (2018) First-in-human evaluation of the Cleveland Multiport Catheter for convection-enhanced delivery of topotecan in recurrent high-grade glioma: results of pilot trial 1. J Neurosurg 130:1–10: https://doi.org/10.3171/2017.10.JNS171845CrossRef

33.

D'Amico RS, Neira JA, Yun J, Alexiades NG, Banu M, Englander ZK, Kennedy BC, Ung TH, Rothrock RJ, Romanov A, Guo X, Zhao B, Sonabend AM, Canoll P, Bruce JN (2019) Validation of an effective implantable pump-infusion system for chronic convection-enhanced delivery of intracerebral topotecan in a large animal model. J Neurosurg 1:1–10: https://doi.org/10.3171/2019.3.JNS1963CrossRef

34.

Chen PY, Ozawa T, Drummond DC, Kalra A, Fitzgerald JB, Kirpotin DB, Wei KC, Butowski N, Prados MD, Berger MS, Forsayeth JR, Bankiewicz K, James CD (2013) Comparing routes of delivery for nanoliposomal irinotecan shows superior anti-tumor activity of local administration in treating intracranial glioblastoma xenografts. Neuro Oncol 15:189–197. https://doi.org/10.1093/neuonc/nos305CrossRefPubMed

35.

Raghavan R, Brady ML, Rodriguez-Ponce MI, Hartlep A, Pedain C, Sampson JH (2006) Convection-enhanced delivery of therapeutics for brain disease, and its optimization. Neurosurg Focus 20:E12. https://doi.org/10.3171/foc.2006.20.4.7CrossRefPubMed

36.

Healy AT, Vogelbaum MA (2015) Convection-enhanced drug delivery for gliomas. Surg Neurol Int 6:S59–67. https://doi.org/10.4103/2152-7806.151337CrossRefPubMedPubMedCentral

37.

Linninger AA, Somayaji MR, Mekarski M, Zhang L (2008) Prediction of convection-enhanced drug delivery to the human brain. J Theor Biol 250:125–138. https://doi.org/10.1016/j.jtbi.2007.09.009CrossRefPubMed

38.

Lonser RR, Warren KE, Butman JA, Quezado Z, Robison RA, Walbridge S, Schiffman R, Merrill M, Walker ML, Park DM, Croteau D, Brady RO, Oldfield EH (2007) Real-time image-guided direct convective perfusion of intrinsic brainstem lesions: technical note. J Neurosurg 107:190–197. https://doi.org/10.3171/JNS-07/07/0190CrossRefPubMed

39.

Bruce JN, Falavigna A, Johnson JP, Hall JS, Birch BD, Yoon JT, Wu EX, Fine RL, Parsa AT (2000) Intracerebral clysis in a rat glioma model. Neurosurgery 46:683–691CrossRef

40.

Burris HA, 3rd (1998) Topotecan: Incorporating It Into the Treatment of Solid Tumors. Oncologist 3:1–3CrossRef

41.

Kaiser MG, Parsa AT, Fine RL, Hall JS, Chakrabarti I, Bruce JN (2000) Tissue distribution and antitumor activity of topotecan delivered by intracerebral clysis in a rat glioma model. Neurosurgery 47:1391–1398; discussion 1398-1399CrossRef

42.

Matsumoto Y, Fujiwara T, Honjo Y, Sasaoka N, Tsuchida T, Nagao S (1993) Quantitative analysis of DNA topoisomerase I activity in human and rat glioma: characterization and mechanism of resistance to antitopoisomerase chemical, camptothecin-11. J Surg Oncol 53:97–103CrossRef

43.

Jahangiri A, Chin AT, Flanigan PM, Chen R, Bankiewicz K, Aghi MK (2017) Convection-enhanced delivery in glioblastoma: a review of preclinical and clinical studies. J Neurosurg 126:191–200. https://doi.org/10.3171/2016.1.JNS151591CrossRefPubMed

44.

Weber F, Asher A, Bucholz R, Berger M, Prados M, Chang S, Bruce J, Hall W, Rainov NG, Westphal M, Warnick RE, Rand RW, Floeth F, Rommel F, Pan H, Hingorani VN, Puri RK (2003) Safety, tolerability, and tumor response of IL4-Pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma. J Neurooncol 64:125–137PubMed

45.

Sampson JH, Akabani G, Archer GE, Berger MS, Coleman RE, Friedman AH, Friedman HS, Greer K, Herndon JE, 2nd, Kunwar S, McLendon RE, Paolino A, Petry NA, Provenzale JM, Reardon DA, Wong TZ, Zalutsky MR, Pastan I, Bigner DD (2008) Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors. Neuro Oncol 10:320–329. https://doi.org/10.1215/15228517-2008-012CrossRefPubMedPubMedCentral

46.

Kunwar S, Chang S, Westphal M, Vogelbaum M, Sampson J, Barnett G, Shaffrey M, Ram Z, Piepmeier J, Prados M, Croteau D, Pedain C, Leland P, Husain SR, Joshi BH, Puri RK, Group PS (2010) Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma. Neuro Oncol 12:871–881. https://doi.org/10.1093/neuonc/nop054CrossRef

47.

Mueller S, Polley MY, Lee B, Kunwar S, Pedain C, Wembacher-Schroder E, Mittermeyer S, Westphal M, Sampson JH, Vogelbaum MA, Croteau D, Chang SM (2011) Effect of imaging and catheter characteristics on clinical outcome for patients in the PRECISE study. J Neurooncol 101:267–277. https://doi.org/10.1007/s11060-010-0255-0CrossRefPubMed

48.

Felgner JH, Kumar R, Sridhar CN, Wheeler CJ, Tsai YJ, Border R, Ramsey P, Martin M, Felgner PL (1994) Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations. J Biol Chem 269:2550–2561CrossRef

49.

Zhu J, Zhang L, Hanisch UK, Felgner PL, Reszka R (1996) A continuous intracerebral gene delivery system for in vivo liposome-mediated gene therapy. Gene Ther 3:472–476PubMed

50.

Klatzmann D, Valery CA, Bensimon G, Marro B, Boyer O, Mokhtari K, Diquet B, Salzmann JL, Philippon J (1998) A phase I/II study of herpes simplex virus type 1 thymidine kinase "suicide" gene therapy for recurrent glioblastoma. Study Group on Gene Therapy for Glioblastoma. Hum Gene Ther 9:2595–2604. https://doi.org/10.1089/hum.1998.9.17-2595CrossRefPubMed

51.

Ram Z, Culver KW, Oshiro EM, Viola JJ, DeVroom HL, Otto E, Long Z, Chiang Y, McGarrity GJ, Muul LM, Katz D, Blaese RM, Oldfield EH (1997) Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat Med 3:1354–1361CrossRef

52.

Dewey RA, Morrissey G, Cowsill CM, Stone D, Bolognani F, Dodd NJ, Southgate TD, Klatzmann D, Lassmann H, Castro MG, Lowenstein PR (1999) Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: implications for clinical trials. Nat Med 5:1256–1263. https://doi.org/10.1038/15207CrossRefPubMed

53.

Eck SL, Alavi JB, Alavi A, Davis A, Hackney D, Judy K, Mollman J, Phillips PC, Wheeldon EB, Wilson JM (1996) Treatment of advanced CNS malignancies with the recombinant adenovirus H5.010RSVTK: a phase I trial. Hum Gene Ther 7:1465–1482. https://doi.org/10.1089/hum.1996.7.12-1465CrossRefPubMed

54.

Ren H, Boulikas T, Lundstrom K, Soling A, Warnke PC, Rainov NG (2003) Immunogene therapy of recurrent glioblastoma multiforme with a liposomally encapsulated replication-incompetent Semliki forest virus vector carrying the human interleukin-12 gene—a phase I/II clinical protocol. J Neurooncol 64:147–154PubMed

55.

Brown MC, Holl EK, Boczkowski D, Dobrikova E, Mosaheb M, Chandramohan V, Bigner DD, Gromeier M, Nair SK (2017) Cancer immunotherapy with recombinant poliovirus induces IFN-dominant activation of dendritic cells and tumor antigen-specific CTLs. Sci Transl Med 9:eaan4220. https://doi.org/10.1126/scitranslmed.aan4220CrossRefPubMedPubMedCentral

56.

Casanova F, Carney PR, Sarntinoranont M (2014) Effect of needle insertion speed on tissue injury, stress, and backflow distribution for convection-enhanced delivery in the rat brain. PLoS ONE 9:e94919. https://doi.org/10.1371/journal.pone.0094919CrossRefPubMedPubMedCentral

57.

Sillay KA, McClatchy SG, Shepherd BA, Venable GT, Fuehrer TS (2014) Image-guided convection-enhanced delivery into agarose gel models of the brain. J Vis Exp. https://doi.org/10.3791/51466CrossRefPubMedPubMedCentral

58.

Lonser RR, Walbridge S, Garmestani K, Butman JA, Walters HA, Vortmeyer AO, Morrison PF, Brechbiel MW, Oldfield EH (2002) Successful and safe perfusion of the primate brainstem: in vivo magnetic resonance imaging of macromolecular distribution during infusion. J Neurosurg 97:905–913. https://doi.org/10.3171/jns.2002.97.4.0905CrossRefPubMed

59.

Krauze MT, Saito R, Noble C, Tamas M, Bringas J, Park JW, Berger MS, Bankiewicz K (2005) Reflux-free cannula for convection-enhanced high-speed delivery of therapeutic agents. J Neurosurg 103:923–929. https://doi.org/10.3171/jns.2005.103.5.0923CrossRefPubMed

60.

Allard E, Passirani C, Benoit JP (2009) Convection-enhanced delivery of nanocarriers for the treatment of brain tumors. Biomaterials 30:2302–2318. https://doi.org/10.1016/j.biomaterials.2009.01.003CrossRefPubMed

61.

Boucher Y, Baxter LT, Jain RK (1990) Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy. Cancer Res 50:4478–4484PubMed

62.

Yang X, Saito R, Nakamura T, Zhang R, Sonoda Y, Kumabe T, Forsayeth J, Bankiewicz K, Tominaga T (2016) Peri-tumoral leakage during intra-tumoral convection-enhanced delivery has implications for efficacy of peri-tumoral infusion before removal of tumor. Drug Deliv 23:781–786. https://doi.org/10.3109/10717544.2014.914987CrossRefPubMed

63.

Raghavan R, Brady ML, Sampson JH (2016) Delivering therapy to target: improving the odds for successful drug development. Ther Deliv 7:457–481. https://doi.org/10.4155/tde-2016-0016CrossRefPubMed

64.

Brady ML, Raghavan R, Alexander A, Kubota K, Sillay K, Emborg ME (2013) Pathways of infusate loss during convection-enhanced delivery into the putamen nucleus. Stereotact Funct Neurosurg 91:69–78. https://doi.org/10.1159/000342492CrossRefPubMedPubMedCentral

65.

Yang W, Barth RF, Huo T, Nakkula RJ, Weldon M, Gupta N, Agius L, Grecula JC (2014) Radiation therapy combined with intracerebral administration of carboplatin for the treatment of brain tumors. Radiat Oncol 9:25. https://doi.org/10.1186/1748-717X-9-25CrossRefPubMedPubMedCentral

66.

Debinski W, Tatter SB (2009) Convection-enhanced delivery for the treatment of brain tumors. Expert Rev Neurother 9:1519–1527. https://doi.org/10.1586/ern.09.99CrossRefPubMedPubMedCentral

67.

Chen MY, Lonser RR, Morrison PF, Governale LS, Oldfield EH (1999) Variables affecting convection-enhanced delivery to the striatum: a systematic examination of rate of infusion, cannula size, infusate concentration, and tissue-cannula sealing time. J Neurosurg 90:315–320. https://doi.org/10.3171/jns.1999.90.2.0315CrossRefPubMed

68.

Bidros DS, Liu JK, Vogelbaum MA (2010) Future of convection-enhanced delivery in the treatment of brain tumors. Future Oncol 6:117–125. https://doi.org/10.2217/fon.09.135CrossRefPubMed

69.

Kunwar S, Prados MD, Chang SM, Berger MS, Lang FF, Piepmeier JM, Sampson JH, Ram Z, Gutin PH, Gibbons RD, Aldape KD (2007) Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. J Clin Oncol 25:837–844. https://doi.org/10.1200/JCO.2006.08.1117CrossRefPubMed

70.

Mehta AI, Choi BD, Raghavan R, Brady M, Friedman AH, Bigner DD, Pastan I, Sampson JH (2011) Imaging of convection enhanced delivery of toxins in humans. Toxins (Basel) 3:201–206. https://doi.org/10.3390/toxins3030201CrossRef

71.

Sampson JH, Raghavan R, Brady ML, Provenzale JM, Herndon JE, 2nd, Croteau D, Friedman AH, Reardon DA, Coleman RE, Wong T, Bigner DD, Pastan I, Rodriguez-Ponce MI, Tanner P, Puri R, Pedain C (2007) Clinical utility of a patient-specific algorithm for simulating intracerebral drug infusions. Neuro Oncol 9:343–353. https://doi.org/10.1215/15228517-2007-007CrossRefPubMedPubMedCentral

Title: Convection-enhanced drug delivery for glioblastoma: a review
Authors: Randy S. D’Amico
Manish K. Aghi
Michael A. Vogelbaum
Jeffrey N. Bruce
Publication date: 01-02-2021
Publisher: Springer US
Keywords: Glioblastoma
Glioma
Glioma
Glioblastoma
Brain Tumor
Glioblastoma
Glioma
Published in: Journal of Neuro-Oncology / Issue 3/2021
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-020-03408-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Convection-enhanced drug delivery for glioblastoma: a review

Abstract

Introduction

Materials and methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Materials and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2021

Laser interstitial thermotherapy (LITT) for the treatment of tumors of the brain and spine: a brief review

Neurosurgical involvement in clinical trials for CNS tumors

Beyond guidelines: analysis of current practice patterns of AANS/CNS tumor neurosurgeons

Introduction to special issue dedicated to the 35th anniversary of the joint section on tumors

Fluorescence guided surgery for pituitary adenomas

Combination immunotherapy strategies for glioblastoma